Pirenzepine monohydrate | 84827-28-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: Pirenzepine monohydrate
• 英文别名: 11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one;hydrate
• CAS: 84827-28-1
• 化学式: C19H23N5O3
• 分子量: 369.4
• InChiKey: IQRQONJNYNFBJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.73
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  69.8
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• METHODS AND COMPOSITIONS FOR TREATMENT OF PERIPHERAL NEUROPATHIES
  申请人：University of Manitoba

  公开号：EP3895705A2

  公开（公告）日：2021-10-20

  A composition for therapy of a peripheral neuropathy disorder in a subject in need thereof. The composition comprises an effective amount of an agent selected from a group consisting of pirenzepine, oxybutynin, muscarinic toxin 7, a muscarinic receptor antagonist, and combinations thereof, and a pharmacologically acceptable carrier and/or an excipient. The composition is useful for therapy of peripheral neuropathies exemplified by peripheral neuropathies induced by systemic diseases, peripheral neuropathies induced by metabolic diseases, chemotherapy-induced peripheral neuropathies, compression-induced peripheral neuropathies, peripheral neuropathies induced by exposure to dichloroacetate, immune-mediated peripheral neuropathies, peripheral neuropathies induced by infections, and genetically acquired peripheral neuropathies.

  一种用于治疗有需要的受试者周围神经病变疾病的组合物。该组合物包含有效量的选自哌仑西平、奥布宁、毒蕈碱毒素 7、毒蕈碱受体拮抗剂及其组合的药剂，以及药理学上可接受的载体和/或赋形剂。该组合物可用于治疗周围神经病，例如全身性疾病诱发的周围神经病、代谢性疾病诱发的周围神经病、化疗诱发的周围神经病、压迫诱发的周围神经病、暴露于二氯乙酸诱发的周围神经病、免疫介导的周围神经病、感染诱发的周围神经病以及遗传获得性周围神经病。
• THERAPEUTIC COMPOSITIONS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY
  申请人：Fernyhough Paul

  公开号：US20130267506A1

  公开（公告）日：2013-10-10

  Compositions for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof, the compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.